Ga-68-PSMA PET/CT for prostate cancer;Ga-68-PSMA-PET/CT bei prostatakarzinom

Aktuelle Urologie

Volumn 45, Issue 6, 2014, Pages 457-463

  Hellwig, D ^a,b   Moosbauer, J ^b   Eilles, C ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Ga 68 Glu NH CO NH Lys(Ahx) HBED CC; PET CT; prostate cancer; PSMA

Indexed keywords

EDETIC ACID; GALLIUM; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; OLIGOPEPTIDE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COMPARATIVE STUDY; HUMAN; IMAGE ENHANCEMENT; MALE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

ANTIGENS, SURFACE; EDETIC ACID; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; RADIOGRAPHIC IMAGE ENHANCEMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84918781108     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0034-1395529     Document Type: Article

References (46)

1. Afshar-Oromieh A, Haberkorn U, Eder M et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086
2. Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495
3. Afshar-Oromieh A, Zechmann C M, Malcher A et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 11-20
4. Bander N H, Milowsky M I, Nanus D M et al. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 2005; 23: 4591-4601
5. Bauman G, Belhocine T, Kovacs M et al. 18 F-fluorocholine for prostate cancer imaging: A systematic review of the literature. Prostate Cancer and Prostatic Diseases 2012; 15: 45-55
6. Beheshti M, Haim S, Zakavi R et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 2013; 54: 833-840
7. Beheshti M, Langsteger W, Sommerhuber A et al. BAY 1075553 in staging and re-staging of prostate cancer patients-Phase I study and comparison to 18F-FCH. J Nucl Med 2012; 53 (Suppl 1): 272
8. Chang S S, O'Keefe D S, Bacich D J et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clinical Cancer Research 1999; 5: 2674-2681
9. Chang S S, Reuter V E, Heston W D et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001; 57: 801-805
10. Cho S Y, Gage K L, Mease R C et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012; 53: 1883-1891
11. Davis M I, Bennett M J, Thomas L M et al. Crystal structure of prostatespecifi c membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 981-986
12. De Angelis R, Sant M, Coleman M P et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23-34
13. Eder M, Eisenhut M, Babich J et al. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40: 819-823
14. Eder M, Schafer M, Bauder-Wust U et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688-697
15. Eder M, Wangler B, Knackmuss S et al. Tetrafluorophenolate of HBEDCC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies. Eur J Nucl Med Mol Imaging 2008; 35: 1878-1886
16. Ghosh A, Heston W D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539
17. Graham K, Kettschau G, Gromov A et al. [18F]-labeled PET tracer BAY1075553, small molecule inhibitor of PSMA for molecular Imaging of prostate cancer. World. Molecular. Imaging. Conference 2011; 235
18. Haffner M C, Kronberger I E, Ross J S et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology 2009; 40: 1754-1761
19. Hillier S M, Kern A M, Maresca K P et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is eff ective at monitoring tumor response to taxane therapy. J Nucl Med 2011; 52: 1082-1093
20. Hillier S M, Maresca K P, Femia F J et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Research 2009; 69: 6932-6940
21. Hofer C, Laubenbacher C, Block T et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. European Urology 1999; 36: 31-35
22. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011; 52: 81-89
23. Kozikowski A P, Nan F, Conti P et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) [1]. Journal of Medicinal Chemistry 2001; 44: 298-301
24. Li Y, Cozzi P J, Russell P J. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010; 30: 67-101
25. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629-3634
26. Maresca K P, Hillier S M, Femia F J et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. Journal of Medicinal Chemistry 2009; 52: 347-357
27. Mease R C, Dusich C L, Foss C A et al. N-[N-[(S)-1,3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008; 14: 3036-3043
28. Mease R C, Foss C A, Pomper M G. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 2013; 13: 951-962
29. Osborne J R, Akhtar N H, Vallabhajosula S et al. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013; 31: 144-154
30. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5: 101-106
31. Perner S, Hofer M D, Kim R et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701
32. Picchio M, Briganti A, Fanti S et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59: 51-60
33. Rajasekaran S A, Anilkumar G, Oshima E et al. A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen. Molecular Biology of the Cell 2003; 14: 4835-4845
34. Reske S N, Winter G, Baur B et al. Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 969-970
35. Robert Koch-Institut. (Hrsg.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg.). 2013. Krebs in Deutschland 2009/2010. Berlin
36. Ross A E, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-2816
37. Ross J S, Sheehan C E, Fisher H A et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-6362
38. Silver D A, Pellicer I, Fair W R et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research 1997; 3: 81-85
39. Smith-Jones P M, Vallabhajosula S, Navarro V et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. Journal of Nuclear Medicine 2003; 44: 610-617
40. Stephenson A J, Scardino P T, Kattan M W et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-2041
41. Tagawa S T, Milowsky M I, Morris M et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical Cancer Research 2013; 19: 5182-5191
42. Trock B J, Han M, Freedland S J et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-2769
43. Troyer J K, Beckett M L, Wright G L Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. International Journal of Cancer 1995; 62: 552-558
44. Wang W, Tavora F, Sharma R et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol 2009; 27: 525-528
45. Wirth M, Weiinnodatabetabach L, Ackermann R et al. Interdisziplinäre Leitlinie der Qualität S3 Zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Aktualisierung 2011. Deutsche Gesellschaft für Urologie e. V. 2011;
46. Wright G L Jr, Grob B M, Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334